MedWellAI Expands Series B Preferred Stock Authorization

MedWellAI ( (MWAI) ) has provided an update.

On April 16, 2026, MedWellAI, Inc. filed a Certificate of Amendment with the Nevada Secretary of State to modify the terms governing its Series B Convertible Preferred Stock. The amendment increases the designated and authorized Series B Convertible Preferred Stock from 1,000,000 to 1,500,000 shares, while leaving all other provisions of the existing Certificate of Designation, originally filed in 2015 and corrected in 2016, in full force and effect.

This move expands the company’s capacity to issue additional preferred equity, which may support future capital-raising efforts and enhance financial flexibility. The change could influence MedWellAI’s capital structure and potential dilution dynamics, carrying implications for existing shareholders and prospective investors as the company manages its financing needs.

Spark’s Take on MWAI Stock

According to Spark, TipRanks’ AI Analyst, MWAI is a Neutral.

The score is held down primarily by weak financial performance (volatile revenue, persistent heavy losses, ongoing cash burn, and negative equity). Technicals are also soft with the stock trading below major moving averages and negative MACD. Valuation provides limited offset given the negative P/E and lack of dividend data.

To see Spark’s full report on MWAI stock, click here.

More about MedWellAI

MedWellAI, Inc. operates in the healthcare and medical technology sector and is structured with multiple classes of equity, including Series B Convertible Preferred Stock. The company’s capital structure allows it to issue preferred shares that can be converted into common stock, providing flexibility in financing and investor participation.

Average Trading Volume: 3,724

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.14M

For detailed information about MWAI stock, go to TipRanks’ Stock Analysis page.